Business Wire

Concert Pharmaceuticals Presents CTP-543 Data from Long-Term Extension Study in Alopecia Areata During Late-Breaking Session at EADV Congress

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented initial data from the ongoing long-term, open-label extension study of the investigational medicine ...
Nasdaq

Concert Pharmaceuticals Presents Update on CTP-543 Long-Term Extension Study in Alopecia Areata During 2nd JAK Inhibitors Drug Development Summit

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today will present an update from its ongoing open label, long-term extension study of the investigational medicine CTP ...
Monthly Prescribing Reference

Study Investigating Oral JAK Inhibitor for Alopecia Areata Meets Endpoint

CTP-543 is an investigational oral selective inhibitor of JAK1 and JAK2. Positive topline results were announced from a second phase 3 trial evaluating the efficacy and safety of CTP-543 in adults ...